A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.
Also called NCT01554982
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 168 participants
- Sponsor
- Registry
-
NCT01554982
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT01554982. Allocation not applicable; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2016-07-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
- Condition
- End Stage Renal Disease
- Condition
- Kidney Failure
- Condition
- Renal Failure
- Condition
- Hyperphosphatemia
- Condition
- ESRD
- Intervention (Drug)
- ferric citrate
- Lead sponsor
- Keryx Biopharmaceuticals
Record details
- Record id
cardio:ct-nct01554982- Content hash
5e2dfe2e8b228120d93824df30b84a1add54fe9a4e8af4ce04c29fd86d931b1e